Sign up to save your podcasts
Or
Share ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
In this edition of The Weekly, Managing Editor
Jef Akst and News Editor Greg Slabodkin share their insights from the American Society of Gene
& Cell Therapy’s 27th annual conference, including advances around adeno-associated viruses and the
ongoing discussion about the FDA’s accelerated approval program and how it relates to rare diseases.
Also, on Tuesday, Eli Lilly announced that an advisory committee meeting will be held for its Alzheimer’s drug donanemab on June 10. Lilly is aiming for full approval of the anti-amyloid antibody after accelerated approval was denied in January 2023. And the race between Vertex and bluebird bio’s gene therapies Casgevy and Lyfgenia is heating up.
View all episodes
By BioSpace
4.9
1313 ratings
In this edition of The Weekly, Managing Editor
Jef Akst and News Editor Greg Slabodkin share their insights from the American Society of Gene
& Cell Therapy’s 27th annual conference, including advances around adeno-associated viruses and the
ongoing discussion about the FDA’s accelerated approval program and how it relates to rare diseases.
Also, on Tuesday, Eli Lilly announced that an advisory committee meeting will be held for its Alzheimer’s drug donanemab on June 10. Lilly is aiming for full approval of the anti-amyloid antibody after accelerated approval was denied in January 2023. And the race between Vertex and bluebird bio’s gene therapies Casgevy and Lyfgenia is heating up.
More shows like BioSpace
View all
This American Life
91,010 Listeners
Planet Money
30,856 Listeners
Hidden Brain
43,717 Listeners
Marketplace
8,777 Listeners
Exchanges
962 Listeners
WSJ What’s News
4,361 Listeners
Bloomberg Surveillance
1,177 Listeners
Odd Lots
1,986 Listeners
Up First from NPR
56,898 Listeners
The Indicator from Planet Money
9,564 Listeners
The Readout Loud
334 Listeners
The Journal.
6,083 Listeners
Short Wave
6,562 Listeners
BioCentury This Week
35 Listeners
Biotech Hangout
21 Listeners